Skip to content
value.today

Maxymune Therapeutics, Inc.

🇺🇸 Los Altos, California, USABiotechnologyFounded 2023

Formerly Transplant RX, Inc.

Total raised
$3 M
1 round on record
Latest round
$3 M
Feb 2025
First round on record
Feb 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Maxymune Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$3 MNo. 1$2 to $10 million

Maxymune Therapeutics, Inc.: Raise no. 1, Feb 2025

Investors in this round

15 investors had bought by the notice of Jun 3, 2026: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
$10,000
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gordon Ringold · Executive Officer, Director
  • Tatjana Naranda · Executive Officer, Director
  • Neil Solomons · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tatjana Naranda, President & COO. Newest notice filed Jun 3, 2026. Read the notice at the SEC.

optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Maxymune Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Jun 2026).

    SEC Form D (revenue range) · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Maxymune Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Maxymune Therapeutics, Inc.
NameRoleNamed in
Gordon RingoldExecutive officerJun 2026
Tatjana NarandaExecutive officerJun 2026
Gordon RingoldDirectorJun 2026
Neil SolomonsDirectorJun 2026
Tatjana NarandaDirectorJun 2026